Congenital Hepatitis B Virus Infections

Introduction to Congenital Hepatitis B Virus Infections

Congenital Hepatitis B Virus (HBV) infection occurs when an infant is infected with HBV from their mother during pregnancy or at birth. This vertical transmission is a significant global health concern, particularly in regions with high HBV prevalence.

Key points:

  • Global prevalence: Approximately 257 million people living with chronic HBV infection worldwide
  • Vertical transmission risk: 70-90% for HBeAg-positive mothers without intervention
  • Chronic infection risk: 90% for infants infected perinatally
  • Geographic variation: Higher prevalence in Asia, Africa, Pacific Islands, and parts of South America

Transmission and Risk Factors

Vertical transmission of HBV can occur through several routes:

  1. Intrauterine transmission: Occurs in about 5-10% of cases
    • Associated with maternal HBeAg positivity and high viral load
    • May occur through placental leakage or cellular transfer
  2. Intrapartum transmission: Most common route (90% of cases)
    • Occurs during labor and delivery through maternal blood and genital secretions
    • Risk increased with prolonged labor and invasive procedures
  3. Postpartum transmission: Can occur through close contact or breastfeeding
    • Risk is low if proper precautions are taken

Risk Factors for Vertical Transmission:

  • High maternal HBV DNA levels (>200,000 IU/mL or >10⁶ copies/mL)
  • Maternal HBeAg positivity
  • Acute HBV infection during pregnancy
  • Previous child with HBV infection
  • Lack of appropriate immunoprophylaxis at birth
  • Invasive procedures during pregnancy or delivery (e.g., amniocentesis, forceps delivery)
  • Prolonged labor
  • Preterm birth

Pathophysiology of Congenital HBV Infection

The pathophysiology of congenital HBV infection involves several key processes:

  1. Viral entry and replication:
    • HBV enters hepatocytes via the sodium taurocholate cotransporting polypeptide (NTCP) receptor
    • Viral DNA is converted to covalently closed circular DNA (cccDNA) in the nucleus
    • cccDNA serves as a template for viral replication and persistence
  2. Immune tolerance:
    • Neonatal immune system is relatively immature
    • Exposure to maternal HBeAg in utero may induce T-cell tolerance to HBV antigens
    • Results in high rates of chronic infection in perinatally infected infants
  3. Liver damage:
    • Initially minimal due to immune tolerance
    • Later stages may involve immune-mediated liver injury
  4. Viral persistence:
    • Integration of HBV DNA into host genome
    • Persistence of cccDNA in hepatocytes

The interplay between viral factors and the developing immune system largely determines the course of infection in congenitally infected infants.

Clinical Manifestations of Congenital HBV Infection

The clinical presentation of congenital HBV infection can vary widely, from asymptomatic to severe liver disease:

Acute Phase:

  • Most infants are asymptomatic during acute infection
  • Rare cases may present with:
    • Jaundice
    • Fever
    • Fatigue
    • Abdominal pain
    • Nausea and vomiting

Chronic Phase:

The natural history of chronic HBV infection acquired perinatally typically involves several phases:

  1. Immune tolerant phase:
    • High HBV DNA levels
    • HBeAg positivity
    • Normal or minimally elevated ALT levels
    • Minimal liver inflammation or fibrosis
    • Can last for decades in perinatally infected individuals
  2. Immune active phase:
    • Elevated ALT levels
    • Fluctuating HBV DNA levels
    • Progressive liver inflammation and fibrosis
  3. Inactive carrier phase:
    • Low HBV DNA levels
    • HBeAg negativity, anti-HBe positivity
    • Normal ALT levels
  4. Reactivation phase:
    • Can occur spontaneously or due to immunosuppression
    • Elevated HBV DNA and ALT levels

Extrahepatic Manifestations:

  • Glomerulonephritis
  • Vasculitis
  • Polyarteritis nodosa
  • Aplastic anemia (rare)

Long-term Complications:

  • Cirrhosis
  • Hepatocellular carcinoma (HCC)
  • Liver failure

Diagnosis of Congenital HBV Infection

Diagnosis of congenital HBV infection involves both maternal screening and infant testing:

Maternal Screening:

  • HBsAg testing is recommended for all pregnant women
  • If HBsAg-positive:
    • Test for HBeAg, anti-HBe, and HBV DNA levels
    • Assess liver function (ALT, AST, bilirubin)
    • Screen for co-infections (HIV, HCV)

Infant Diagnosis:

  1. Serological testing:
    • HBsAg: Test at 9-12 months of age or 1-2 months after completion of HBV vaccine series
    • Anti-HBs: To confirm vaccine response
  2. HBV DNA PCR:
    • Can be used for earlier diagnosis (1-3 months of age)
    • Particularly useful in high-risk infants or research settings
  3. Liver function tests:
    • ALT, AST, bilirubin, albumin, prothrombin time

Interpretation of Results:

  • HBsAg positivity beyond 6 months of age indicates chronic HBV infection
  • Presence of anti-HBs without HBsAg indicates successful immunization
  • HBsAg negativity with absent anti-HBs may indicate vaccine non-response

Additional Assessments:

  • Liver ultrasound: To assess for liver abnormalities or HCC
  • Liver biopsy: May be considered in certain cases to assess disease severity
  • Hepatitis B genotyping: May guide treatment decisions in some cases

Management and Prevention of Congenital HBV Infection

Management of congenital HBV infection focuses on prevention through maternal treatment and infant immunoprophylaxis:

Maternal Management:

  1. Antiviral therapy during pregnancy:
    • Recommended for mothers with high viral load (>200,000 IU/mL)
    • Typically started at 28-32 weeks gestation
    • Preferred agents: Tenofovir disoproxil fumarate (TDF) or Telbivudine
  2. Monitoring:
    • Regular liver function tests and HBV DNA levels
    • Assess for complications and co-infections
  3. Delivery considerations:
    • Cesarean section not routinely recommended solely for HBV status
    • Avoid invasive procedures when possible

Infant Management:

  1. Immunoprophylaxis:
    • Hepatitis B immune globulin (HBIG): 0.5 mL IM within 12 hours of birth
    • HBV vaccine: First dose within 12 hours of birth, followed by complete series
  2. Monitoring:
    • Serological testing at 9-12 months of age
    • Regular follow-up for HBsAg-positive infants
  3. Treatment of chronic HBV:
    • Not typically indicated in young children due to immune tolerance phase
    • May be considered in cases of severe liver disease or family history of HCC

Prevention Strategies:

  • Universal screening of pregnant women for HBsAg
  • Antiviral therapy for high-risk mothers
  • Timely administration of HBIG and HBV vaccine to infants
  • Completion of HBV vaccine series for all infants
  • Post-vaccination serological testing for infants of HBsAg-positive mothers
  • Education about HBV transmission and prevention

Prognosis and Long-term Outcomes

The prognosis for individuals with congenital HBV infection varies, but many face significant long-term health risks:

Natural History:

  • 90% of perinatally infected infants develop chronic HBV infection
  • 25-40% of chronically infected individuals develop serious sequelae in their lifetime

Long-term Complications:

  1. Cirrhosis:
    • Risk of 2-5% per year in chronic HBV infection
    • Cumulative incidence of 8-20% over 5 years
  2. Hepatocellular Carcinoma (HCC):
    • Annual incidence of 2-5% in patients with cirrhosis
    • Can occur in non-cirrhotic patients, especially with perinatally acquired HBV
  3. Liver failure:
    • Can occur acutely or as a result of decompensated cirrhosis

Factors Influencing Prognosis:

  • Age at infection (younger age associated with higher chronicity rates)
  • HBeAg status and seroconversion
  • HBV DNA levels
  • ALT levels and patterns
  • HBV genotype
  • Presence of co-infections (HIV, HCV, HDV)
  • Alcohol consumption
  • Metabolic factors (obesity, diabetes)

Monitoring and Follow-up:

  1. Regular liver function tests: Every 6-12 months
  2. HBV DNA levels: Every 6-12 months
  3. HCC surveillance:
    • Liver ultrasound every 6 months for high-risk patients
    • Consider alpha-fetoprotein (AFP) testing
  4. Liver fibrosis assessment:
    • Non-invasive methods: Transient elastography, serum biomarkers
    • Liver biopsy when indicated

Treatment Outcomes:

With appropriate management, outcomes can be improved:

  • Antiviral therapy can suppress viral replication and reduce the risk of complications
  • HBeAg seroconversion can be achieved in 15-30% of treated patients
  • HBsAg loss (functional cure) occurs in 1-3% of treated patients per year
  • Early treatment can reduce the risk of cirrhosis and HCC

Quality of Life:

Chronic HBV infection can impact quality of life due to:

  • Physical symptoms (fatigue, abdominal pain)
  • Psychological effects (anxiety, depression)
  • Social stigma
  • Economic burden of long-term treatment

Future Perspectives:

Research is ongoing to improve outcomes for individuals with congenital HBV infection:

  • Novel antiviral agents and immunomodulators
  • Therapeutic vaccines
  • Strategies to eliminate cccDNA
  • Improved methods for early detection of HCC


Congenital Hepatitis B Virus Infections
  1. What is the primary route of mother-to-child transmission of Hepatitis B Virus (HBV)?
    Answer: Perinatal transmission during labor and delivery.
  2. What percentage of infants born to HBV-positive mothers become chronically infected without intervention?
    Answer: Up to 90% if the mother is HBeAg positive.
  3. What is the recommended timing for the first dose of Hepatitis B vaccine in newborns?
    Answer: Within 24 hours of birth, preferably within 12 hours.
  4. When should Hepatitis B Immunoglobulin (HBIG) be administered to infants born to HBV-positive mothers?
    Answer: Within 12 hours of birth, along with the first dose of vaccine.
  5. What is the efficacy of the combination of HBIG and HBV vaccine in preventing vertical transmission?
    Answer: 85-95% effective when administered properly.
  6. How does maternal HBeAg status affect the risk of vertical transmission?
    Answer: HBeAg-positive mothers have a higher risk of transmitting HBV to their infants.
  7. What is the recommended serological testing for pregnant women to screen for HBV?
    Answer: Hepatitis B surface antigen (HBsAg) testing.
  8. Can HBV be transmitted through breast milk?
    Answer: HBV can be present in breast milk, but breastfeeding is not contraindicated if the infant receives proper prophylaxis.
  9. What is the role of antiviral therapy during pregnancy in preventing vertical transmission?
    Answer: It can reduce maternal viral load and decrease the risk of transmission in high-risk cases.
  10. When should post-vaccination serological testing be performed in infants born to HBV-positive mothers?
    Answer: At 9-12 months of age, testing for HBsAg and anti-HBs.
  11. What is considered a protective anti-HBs level after vaccination?
    Answer: ≥10 mIU/mL
  12. How does cesarean section affect the risk of HBV transmission compared to vaginal delivery?
    Answer: It may slightly reduce the risk, but is not routinely recommended solely for preventing transmission.
  13. What is the risk of intrauterine transmission of HBV?
    Answer: Generally low, accounting for less than 5% of vertical transmissions.
  14. How does maternal HBV viral load affect the risk of transmission?
    Answer: Higher viral loads (typically >200,000 IU/mL) are associated with increased risk of transmission.
  15. What is the recommended HBV vaccine schedule for infants?
    Answer: Birth, 1-2 months, and 6 months of age.
  16. Can amniocentesis increase the risk of HBV transmission to the fetus?
    Answer: Yes, especially in mothers with high viral loads.
  17. What is the long-term risk for infants who become chronically infected with HBV?
    Answer: Increased risk of cirrhosis and hepatocellular carcinoma.
  18. How does maternal co-infection with HIV affect HBV transmission risk?
    Answer: It increases the risk of HBV transmission to the infant.
  19. What is the role of HBV DNA testing in pregnant women?
    Answer: To assess viral load and determine need for antiviral therapy during pregnancy.
  20. Can HBV cause congenital malformations?
    Answer: HBV is not typically associated with congenital malformations.
  21. What is the recommended management for infants born to mothers with unknown HBV status?
    Answer: Administer HBV vaccine within 12 hours of birth and determine maternal HBsAg status as soon as possible.
  22. How does premature rupture of membranes affect HBV transmission risk?
    Answer: Prolonged rupture of membranes may increase the risk of transmission.
  23. What is the significance of isolated anti-HBc positivity in pregnant women?
    Answer: It may indicate occult HBV infection or false-positive result; further evaluation is needed.
  24. How does maternal HBV genotype affect transmission risk?
    Answer: Some genotypes (e.g., genotype C) may be associated with higher transmission risk.
  25. What is the role of HBV surface gene mutations in vaccine failure?
    Answer: Mutations can lead to vaccine escape and transmission despite proper prophylaxis.
  26. How does maternal antiviral therapy affect the safety of breastfeeding?
    Answer: Most antivirals are considered safe during breastfeeding, but individual assessment is necessary.
  27. What is the recommended follow-up for infants who do not develop adequate anti-HBs levels after vaccination?
    Answer: Revaccination with a second 3-dose series.
  28. Can HBV infection in infancy cause acute liver failure?
    Answer: Rarely; most perinatal infections lead to chronic, asymptomatic infection.
  29. What is the role of HBV core promoter mutations in perinatal transmission?
    Answer: They may be associated with increased risk of intrauterine transmission.
  30. How does delayed cord clamping affect the risk of HBV transmission?
    Answer: It is not contraindicated in HBV-positive mothers if proper prophylaxis is given.


Further Reading
Tags:

Powered by Blogger.